Table 1 Sample Characteristics
From: Understanding adjuvant endocrine therapy persistence in breast Cancer survivors
Sample Characteristics N = 22 | Frequency (%) |
|---|---|
Age at diagnosis | |
 18–44 years | – |
 45–60 years | 11 (50) |
 60–79 years | 11 (50) |
Lymph Node Status | |
 Positive | 10 (45) |
 Negative | 12 (55) |
Hormone Status | |
 ER+ | 22 (100) |
 PR+ | 16 (73) |
 Her2+ | 2 (9) |
Treatment History | |
 Surgery | 22 (100) |
 Chemotherapy | 9 (41) |
 Radiation | 18 (82) |
AET Use | |
 Tamoxifen only | 7 (32) |
 AI only | 5 (23) |
 Both tamoxifen and AI | 9 (41) |
 Did not initiate | 1 (5) |
Persistence | |
 Non-persistent | 6 (27) |
 Did not initiate | 1 (5) |
 Persistent | 15 (68) |
Average Perceived Risk of Breast Cancer Recurrence (0–100%) | |
 Non-persistent/did not initiate | 33% |
 Persistent | 29% |